Akshaya Keerti M.D.

My name is Akshaya Keerti, 🇮🇳🇵🇭, a graduate of @MCU1904 and current postdoc research scholar in Infectious Diseases @uofl ( @UofLHealth ). I’m excited to be applying to #Match2026 in #InternalMedicine! AAMC ID: 16769253 Wishing all applicants the best this season! #MedTwitter

@MasterAi254 Guide

I'm deleting this in 24 hours... I found the simplest way to make money with AI: Self-publishing Ebooks. No face. No degree. No writing skills. So I created a Full Guide showing exactly how to do it. • Like this + Comment "Guide" & I'll DM it to you. *Must Follow Me*

@AndrewBolis Hustle

You can earn $7000 each month if you have ChatGPT, a laptop, and 60 mins a day. Usually, I'd charge $79 for this killer guide, but today it's yours 100% FREE. Like + comment "Hustle" and I’ll send you my step-by-step guide for FREE. Must follow me to get DM. FREE for 48 hrs only.

@NadzuAI Start

Claude + Amazon = Daily Income System No skills No stock No risk I usually sell this setup for $199 But right now it’s completely FREE Want access Like this post Comment “START” Repost it Follow me to receive it Inside you’ll get Winning product method Step-by-step setup guide Simple 1-hour daily routine Available for 48 hours only

@AndrewBolis Gpt

21-year-olds are making over $10,000 per month using ChatGPT. Like + comment "GPT" and I'll DM you my step-by-step guide 100% FREE. You must be following me to receive DM now. FREE for the next 48 hours only.

🧬 Classical CD5-based immunophenotypes in B-cell LPDs. 📚 Educational tweet, not medical advice. ✳️ CD5 +ve B-cell LPDs CLL/SLL: CD5+, CD23+, CD200+, Cyclin D1-ve, t(11;14)-ve Mantle Cell Lymphoma: CD5+, CD23-ve, CD200-ve, Cyclin D1+, t(11;14)+, SOX11+ (Useful if cyclin D1 is negative but typically positive in most cases) ✳️ CD5-ve, CD10+ B-cell LPDs Follicular lymphoma: CD5-ve, CD10+, BCL6+, BCL2+, t(14;18)+ [15% cases are BCL2-ve and t(14;18)-ve] Burkitt lymphoma: CD5-ve, CD10+, BCL6+, BCL2-ve, MYC rearranged, Ki-67 ≥95% DLBCL, GCB type: CD5-ve, CD10+, BCL6+, BCL2+, IRF4/MUM1-ve DLBCL with IRF4 rearrangement: CD5-ve, CD10+, BCL6+, IRF4/MUM1+ ✳️ CD5-ve CD10-ve B-cell LPDs Hairy cell leukemia: CD5-ve, CD10-ve, CD103+, CD25+, CD11c+ (Confirmed with CD123+, Annexin A1+, and BRAF V600E mutated) Marginal zone lymphoma: CD5-ve, CD10-ve, CD103-ve, Cytoplasmic Ig+, and MYD88 wild type Lymphoplasmacytic lymphoma (LPL): CD5-ve, CD10-ve, CD103-ve, Cytoplasmic Ig+, and MYD88 mutated DLBCL, GCB: CD5-ve, CD10-ve, BCL6+, IRF4/MUM1-ve DLBCL, Non-GCB: CD5-ve, CD10-ve, BCL6+ve, IRF4/MUM1+ve DLBCL, Post-GCB: CD5-ve, CD10-ve, BCL6-ve, IRF4/MUM1+ 🔑 Key pointers: ‼️DLBCL can present across CD10 expression groups ‼️Post-GCB terminology is per the gene expression profiling (GEP)/molecular classification ‼️MYD88 L265P is mutated in ~90–95% of LPL cases Open for feedback/corrections. [Image AI Generated]

@snaqvi1990 Hello Dr Naqvi. I am currently on a J1. Will the position offer j1 sponsorship? I can switch my visa sponsor without having to go back to home country or taking a visa interview. I am already here in US as a research Assistant.

We are looking for two exceptional Research Assistants! 1) Experimental, to drive forward quantitative studies of transcription factor function in development 2) computational, to develop and apply cutting-edge deep learning models of gene regulation. Links below

@Oliver__Hahn @calico Hello Doc. I’m highly interested in applying for this position. Where do I apply?

🚨 Postdoc position in my lab @calico is live! I'm looking for someone deeply curious about the aging brain🧠⌛️, who wants to build novel scientific projects from scratch and carry them to publication and, ideally, into their own lab🥼🧪. No neuroscience background needed.

@imghelpinghand Intrested

Paid Virtual opportunity We are hiring Tutors for USMLE Step 1 preparation to expand our team. Comment if you have great scores in steps 1 & 2

🚨 Practice-changing 1L PD-L1+ mTNBC data (CPS ≥10) 🚨 ASCENT-04 / KEYNOTE-D19 just compared: 🧬 Sacituzumab govitecan (SG) + Pembrolizumab vs 💉 Chemo (taxane or Gem-Carbo) + Pembrolizumab 📌 Primary endpoint: PFS (BICR) ✅ ⏳ mPFS: 11.2 vs 7.8 months 📉 HR 0.65 (95% CI 0.51–0.84), P <0.001 🎯 ORR: 60% vs 53% ⏱️ DoR: 16.5 vs 9.2 months (much more durable responses 🔥) 🛑 Discontinuation due to AEs: 12% vs 31% (big practical win) ⚠️ Grade ≥3 AEs: 71% vs 70% (similar overall, different toxicity style) 🧠 OS: immature (not reached yet) 💡 Takeaway: SG + Pembro delivers stronger & longer disease control vs chemo + pembro in previously untreated PD-L1+ advanced TNBC. This could be a new frontline backbone if guidelines follow. 👑 🔖 Save this for your next TNBC tumor board 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @asco @stolaney1 @PTarantinoMD

@Nischistocyte Thank you so much @Nischistocyte for the kind words

I think Dr Akshaya will be an asset to any residency program! He is a close friend and a great doctor 🙌🏻😇

We have taller buildings but shorter tempers, more knowledge but less wisdom. Progress means nothing if compassion can’t keep up. 💭 New blog: The Paradox of Progress. hippocampalhermit.blogspot.com/2025/10/the-pa… #ParadoxOfProgress #Empathy #Mindfulness #EmotionalIntelligence #HumanConnection

@NEJM recently published a Letter to the Editor by @ouhealth and @StephensonCC HemOnc Fellow Nishant R. Tiwari, MD @Nischistocyte (senior author), IM Resident Satya Arepalli, MD, and Professor James N. George, MD, on Fetal Hereditary TTP 👏 nejm.org/doi/pdf/10.105…

@RayPortelaMD @MCU1904 @uofl @UofLHealth Thanks. To you too!

@AkshayaKeerti @MCU1904 @uofl @UofLHealth Best of luck, Akshaya!!

My name is Akshaya Keerti, 🇮🇳🇵🇭, a graduate of @MCU1904 and current postdoc research scholar in Infectious Diseases @uofl ( @UofLHealth ). I’m excited to be applying to #Match2026 in #InternalMedicine! AAMC ID: 16769253 Wishing all applicants the best this season! #MedTwitter

@RayPortelaMD @MayoClinic All the best Doc!

Hi #MedTwitter! Excited to be applying for #InternalMedicine this #Match2026. I'm Ray Portela, a Brazilian graduate and postdoctoral research fellow at @MayoClinic. Grateful for my family and mentors during this journey. Wishing everyone the best of luck this interview season!

Osimertinib: shining in trials ✨, stumbling in the real world 🫁 📌 Retrospective US cohort (n=1323) | JTO 2025 🦾 1L Osimertinib in EGFRm NSCLC Median OS: real-world shorter (28.6 mo [vs 38.6 mo in FLAURA]) 📉 2-yr survival: 58% [vs 74%] 5-yr survival: 18% [vs 29%] 29% died before 2L ❌ 33% never received 2L 📊 Risk factors for poor survival: •ECOG ≥2 ⚡ •Liver metastases 🩸 •TP53 co-mutation 🧬 •L858R subtype 🧩 ⚠️ Key insight: 95% of patients carried ≥1 poor-risk feature ➝ real-world outcomes lag far behind trial promise. 🔑 Takeaway: Osimertinib remains standard, but many patients need better frontline strategies, esp. those trial-ineligible. 📓Sabari JK, Yu HA, Mahadevia PJ, et al. J Thorac Oncol 2025. DOI: doi.org/10.1016/j.jtho… #OncoTwitter #MedTwitter #LungCancer #TargetedTherapy @OncoAlert @myesmo @ASCO @IASLC_JTO

@SuyogCancer Hello how to join?

This is growing. We have above 700 members now from all over the world . With different sub groups , we have tumor specific discussions. Those ( practicing oncologists and fellows) who want to join, do DM me 🙂. Join Wisdom without borders 🙂.

@Doctors_GUILD C-much

5 year old boy with jaw swelling. What mutation is to be blamed for а. с-myc b. N-myc c. L-myc d. Kras

@SuyogCancer I’m interested sir. Kindly add me

U can message me on this thread If DM is not open . I will send DM to you to get added to the group.

🌍📚 Calling the global oncology community! We've launched a WhatsApp Academic Group to share: 🔹 Key trial data 🔹 Conference updates 🔹 Oncology posts from X & LinkedIn 🔹 Article links 🔹 Tough case discussions (esp. where no MTB access) Ideal for oncology fellows & practicing oncologists — from LMICs and HICs. 📩 DM me with your mobile number to join. Let’s learn together! #OncoTwitter #MedEd #GlobalOncology

@drakhilkapoor1 Congratulations sir @drakhilkapoor1

🚨 Just published in JCO Global Oncology 📢 Our phase III METRO-CHASE trial shows triple oral metronomic chemotherapy significantly improves survival in platinum-refractory. #HeadAndNeckCancer. 🔗 doi.org/10.1200/GO-25-… #oncology #cancerresearch